error: Invalid attempt to read when no data is present. Patent Office Rejects Lipitor Patent on PUBPAT's Request
Class Action Cases Personal Injury Lawyers Advertise Here Legal Terms
Statute of Limitations Legal Press Releases Legal Articles Site Map
Total Injury
Infinit-i

Home > Article Categories > Legal Press Releases > Patent Office Rejects Lipitor Patent on PUBPAT's Request

Patent Office Rejects Lipitor Patent on PUBPAT's Request

Public Interest Group's Review Results in All 44 Claims of Pfizer's Patent on Multi-Billion Dollar Drug Ruled Invalid
 
In the reexamination proceeding initiated late last year by the Public Patent Foundation ("PUBPAT"), the United States Patent and Trademark Office has rejected all of the claims of Pfizer Inc.'s patent on Lipitor, touted by the pharmaceutical giant as being "the best-selling treatment for lowering cholesterol and the best-selling pharmaceutical product of any kind in the world."

New York (PRWEB) June 22, 2005 -- In the reexamination proceeding initiated late last year by the Public Patent Foundation ("PUBPAT"), the United States Patent and Trademark Office has rejected all of the claims of Pfizer Inc.'s patent on Lipitor, touted by the pharmaceutical giant as being "the best-selling treatment for lowering cholesterol and the best-selling pharmaceutical product of any kind in the world."

Relying on evidence provided by PUBPAT when the reexamination was requested, the Patent Office rejected all 44 claims in the pharmaceutical giant's patent. Pfizer has the opportunity to respond to the Patent Office's rejection, but third party requests for reexamination, like the one filed by PUBPAT, result in having the subject patent either modified or completely revoked roughly 70% of the time.

Although the rejected patent is one of five patents listed by Pfizer with the U.S. Food and Drug Administration (FDA) for atorvastatin, the generic name for the drug compound distributed under the Lipitor brand, it is the only one asserted by Pfizer in roughly two dozen patent infringement lawsuits filed last year against web sites selling generic atorvastatin to Americans. Two of the other listed patents are under review by a Delaware court and the remaining two have never been asserted by Pfizer against any competitor to Lipitor.

"The Patent Office has agreed with our conclusion that it should have never granted Pfizer the Lipitor patent," said Dan Ravicher, PUBPAT's Executive Director. "Revoking Pfizer's patent is a critical step towards providing American consumers with access to atorvastatin at a fair price, which will not only provide substantial economic benefit, but will also improve public health, as even Pfizer admits that many Americans in need of the drug are not getting it."

 




Permission is granted to reproduce this article as long as the above resource paragraph is left in tact with active links.

 





Steven J. Williams, P.C.
Attention Lawyers! Looking to improve business?
Curadebt